SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs10033464

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 3 clinical trials

Clinical Trials


1 Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)

This prospective study aims to examine the association of specific genetic variants (single nucleotide polymorphisms) located on chromosome 1, 4 and 16, with presence of non-pulmonary vein triggers (NPVT) as well as ablation-outcome in AF patients

NCT01751607 Atrial Fibrillation
MeSH: Atrial Fibrillation
HPO: Atrial fibrillation Paroxysmal atrial fibrillation

Previous left atrial catheter ablation or MAZE procedure 2. Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc Atrial Fibrillation Atrial Fibrillation Specific Aim: This prospective pilot study aims to examine the association of specific genetic variants (single nucleotide polymorphisms) namely rs2200733, rs6843082, rs10033464, rs17042171, rs2106261 and rs13376333 on chromosome 1, 4 and 16, with presence of non-pulmonary vein triggers (NPVT) as well as ablation-outcome in AF patients.

Primary Outcomes

Description: Isolation of pulmonary-vein antra and all extra-pulmonary vein triggers

Measure: PVAI and isolation of all non-PV triggers

Time: 1 hour of the ablation procedure

Secondary Outcomes

Description: Recurrence will be defined as freedom from atrial flutter (AFL), AF or atrial tachycardia (AT) of > 30 seconds duration, in the absence of anti-arrhythmic drugs (AADs) at follow-up.

Measure: Recurrence of arrhythmia

Time: Within 1 year of follow-up

2 Detection of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Stroke Patients or TIA Using an Implantable Loop Recorder and Correlation With Genetic Markers.

Atrial fibrillation (AF) is the significant risk factor of ischemic stroke with incidence about 20% of all ischemic strokes. The undiagnosed AF in cryptogenic stroke patients could be present but not revealed by rutinne ECG.

NCT02216370 Cryptogenic Stroke or TIA Atrial Fibrillation
MeSH: Stroke Atrial Fibrillation
HPO: Atrial fibrillation Paroxysmal atrial fibrillation Stroke

Documented Atrial Fibrillation after episode of cryptogenic stroke / TIA Documented genetic mutation PITX2 chromosome 4q25, polymorphism rs1906591,rs10033464 and ZFHX3 chromosome 16q22, polymorphism rs2106261.

Primary Outcomes

Description: Documented Atrial Fibrillation after episode of cryptogenic stroke / TIA Documented genetic mutation PITX2 chromosome 4q25, polymorphism rs1906591,rs10033464 and ZFHX3 chromosome 16q22, polymorphism rs2106261

Measure: Documented Atrial Fibrillation after episode of cryptogenic stroke / TIA Documented genetic mutation PITX2 and ZFHX3

Time: 12 months

Secondary Outcomes

Measure: Time to documented Atrial Fibrillation Reccurent stroke or TIA Stroke Secondary Prevention Therapy changes within 12 months Neuroimaging Changes ( brain CT/ MRI)

Time: 12 months

Other Outcomes

Measure: Follow-up of patients with implanted ECG monitor REVEAL XT incidence of atrial fibrillation, stroke or TIA

Time: 3 Years

3 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

NCT02347111 Atrial Fibrillation Drug: Flecainide Drug: Sotalol
MeSH: Atrial Fibrillation
HPO: Atrial fibrillation Paroxysmal atrial fibrillation

However, a SNP at the 4q25 locus (rs10033464) was significantly associated with successful symptom control (odds ratio [OR] 2.97, 95% confidence interval [CI] 1.42-6.21,

Primary Outcomes

Measure: AF burden (Percent of time subject is in atrial fibrillation)

Time: 3 months


HPO Nodes


Paroxysmal atrial fibrillation
Genes 12
KCNJ5 SCN5A CSRP3 KCNA5 KCNJ2 SCN2B MYL4 ABCC9 TBX5 KCNE2 SCN1B PRKAG2
Stroke
Genes 165
NAGS GDF2 MPL VHL GTF2I CST3 FBN1 SON BAZ1B SLC2A10 MAT2A PRKAG2 TREX1 ND1 SNAP29 TRNH COL4A1 TRNS2 ACAD9 TRNS1 CRELD1 ACVRL1 DPM3 GUCY1A1 CPS1 ND4 GNAQ LMNA RFC2 FOXE3 APP SMAD4 TGFBR2 TPP2 COL4A1 TRNK TRNL1 PRNP GATA4 HBB MYH11 COX2 HTRA1 SLC19A2 ENG TGFB3 PCNT CCM2 PIGA MMUT TRNQ TRNQ MPL MPL GTF2IRD1 SMAD4 TRNS2 ND6 PMM2 MYH11 SMAD4 GYS1 PRKCH ANGPTL6 SCN5A XYLT2 HSD11B2 ACTG1 TRNS1 CBS LIMK1 APP MFAP5 GUCY1A1 DYRK1B MTHFR TRNV SH2B3 COX3 MYH11 ALOX5AP NOS3 ENG NR2F2 TRNL1 ADA2 COX1 SLC19A2 MYD88 GLA JAG1 MLXIPL TP53 TRNW CLIP2 TRNC KRAS TRNF TET2 NOTCH3 ADA2 ND1 NR3C1 GATA6 NPPA ELN RFT1 SMARCAL1 AGXT FLNA TRNW COX3 JAK2 CYP11B1 CYTB F2 SMAD3 APP ACTA2 TNXB OTC APP COL3A1 TET2 ZMPSTE24 PRKG1 MYLK ASS1 TBL2 COX2 WFS1 THPO ELN PIK3C2A CALR JAK2 ENG TGFBR3 TGFB2 ND5 TTR F5 ND6 MECP2 ELN GLA ACTB ACVRL1 COX1 MYBPC3 APP TREX1 ND5 CST3 KCNQ1 COL3A1 ABCC6 ZAP70 TRNF HTRA1 LOX XYLT1 STIM1 JAK2 TGFBR1